COVID-19 has killed more than 2,000 people around the world and infected over 75,600 people. Its origin and ability to spread are unknown, but experts and authorities are already working on how to keep it from breaking out again.
Taiwan's Medigen Vaccine Biologics Corp. (MVC) will cooperate with the U.S. National Institute of Health (NIH) to develop a vaccine against COVID-19. The firm stated that it signed a contract with the U.S. NIH on Feb. 16 which will enable it to obtain the candidate vaccine and related materials developed by the U.S. NIH. While animal testing for vaccine development normally takes four to six months, MVC plans to finish the tests before July this year in order to speed up the process.
On Feb. 20, The University of Texas at Austin and the U.S. NIH released the first 3D image of a key part of the 2019-nCoV coronavirus, giving scientists crucial information about how the virus infects human cells. This could be a critical step toward developing vaccines and treatments.